PMA device
Pearle Vision Monthly Balance
CooperVision, Inc. · Lenses, Soft Contact, Extended Wear (LPM, Class III) · First FDA decision Jan 28, 2020, newest Jan 4, 2022Nearsightedness and refractive error
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
PMA pathway
Device trials
0
Naming "Pearle Vision Monthly"
MAUDE reports
0
Brand "Pearle Vision Monthly", since 2015
PubMed studies
0
Mentioning "Pearle Vision Monthly"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Pearle Vision Monthly Balance
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
- Pearle Vision Monthly BalancePMA supplement
P080011-S130 · Decided Jan 4, 2022 · 175 days after receipt · Normal 180 Day Track No User Fee
Device type: Lenses, soft contact, extended wear (LPM) · Ophthalmology
1 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Hydrophilic Contact LensesNational determinationOn the books80.4Updated Jun 11, 2020
Clinical trials
Device studies on ClinicalTrials.gov that name "Pearle Vision Monthly", any status and sponsor, newest update first.
No registered device study names "Pearle Vision Monthly".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Pearle Vision Monthly", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code LPM
1,788 reports: 19 malfunction, 1,759 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- Biofinity XR Toric Contact LensOpen, Classified
Z-2165-2025 · Started Jun 16, 2025 · Posted by FDA Jul 23, 2025
Reason given: Lens blisters may have an incomplete or leaking seal which may render them unsterile.
Cause as FDA categorized it: Use error · Device type: Lenses, Soft Contact, Extended Wear (LPM)
3 more recall records with a free account
Published research
The most relevant PubMed records for "Pearle Vision Monthly"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code LPM.
- Bausch and Lomb Polymacon Hydrophilic Contact LensesBausch & Lomb, Inc. · PMA 2002
- methafilcon A Soft (Hydrophilic) Extended Wear Contact LensesCooperVision, Inc. · PMA 2019
- Biofinity (Confilcon A) Soft Contact LensesCooperVision, Inc. · PMA 2012
- Sofmed® breathables XW NEXTCooperVision, Inc. · PMA 2025
- up&up Monthly Performance +CooperVision, Inc. · PMA 2025
- VISTAKON® (etafilcon A) Brand Contact LensesVistakon, Johnson & Johnson Vision Products, Inc. · PMA 2022
- VISTAKON® (senofilcon A) Brand Contact LensesVistakon, Division of Johnson & Johnson Vision Car · PMA 2022
- Ethos AquaTech Monthly XR, Ethos AquaTech Monthly XR for AstigmatismCooperVision, Inc. · PMA 2022
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.